Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7026MR)

This product GTTS-WQ7026MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7026MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10103MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ8606MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ14667MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ9738MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ7909MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ11896MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ768MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ2280MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW